Skip to main content
SpringerLink
Log in

Adalimumab/secukinumab

Latent tuberculosis infection and active tuberculosis: 9 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Xiao Y, et al. The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China. Dermatology and Therapy 12: 1493-1500, No. 6, Jun 2022. Available from: URL: http://www.springer.com/springer+healthcare/journal/13555

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/secukinumab. Reactions Weekly 1917, 28 (2022). https://doi.org/10.1007/s40278-022-19899-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-19899-0

Search

Navigation